Levofloxacin Prophylaxis for Pediatric Leukemia Patients: Monitoring of Outcomes for Sustained Benefit and Consequences

Authors

Andrea L Davis
Alexandra M Stevens
Julienne Brackett
Lucila Marquez
Catherine E Foster
Adriana Sarmiento Clemente
Hannah E Sauer
Grant T Stimes
Judith R Campbell

Publication Date

1-1-2024

Journal

Antimicrobial Stewardship & Healthcare Epidemiology

DOI

10.1017/ash.2024.81

PMID

38807931

PMCID

PMC11131004

PubMedCentral® Posted Date

5-22-2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Abstract

Levofloxacin prophylaxis reduces bloodstream infections in neutropenic patients with acute myeloid leukemia or relapsed acute lymphoblastic leukemia. A retrospective, longitudinal cohort study compares incidence of bacteremia, multidrug-resistant organisms (MDRO), and Clostridioides difficile (CDI) between time periods of levofloxacin prophylaxis implementation. Benefits were sustained without increasing MDRO or CDI.